Comparative survey of use of long acting dopamine agonists in current clinical practice: ongoing survey across Europe.
A. Rizos¹, I. Koch¹, G. Durner¹, A. Martin¹, B. Kesse², T. Henriksen³, A. Antonini⁴, P. Odin⁵, C. Falup-Pecurariu⁶, P. Martinez-Martin⁶, P. Reddy¹, Y. Naidu⁹, S. Gay¹⁰ and K. Ray Chaudhuri¹,⁹ on behalf of EUROPAR and EPDA.

¹King’s College Hospital, London, UK; ²Princess Royal University Hospital, Orpington, UK; ³Bispebjerg Hospital, Copenhagen, Denmark; ⁴RCCS San Camillo Venice and University of Padua, Venice, Italy; ⁵Klinikum Reinekenheide, Bremerhaven, Germany; ⁶University Hospital, Lund, Sweden; ⁷University Hospital, Brasov, Romania; ⁸Carlos III Institute of Health and Alzheimer Centre Reina Sofia Foundation, Madrid, Spain; ⁹University Hospital Lewisham, London, UK; ¹⁰St. Thomas’s Hospital, London, UK.

OBJECTIVE:
To address comparative tolerability/retention rates (minimum 6 months use) of longer acting dopamine agonists (DA) such as rotigotine skin patch (RTG), ropinirole (ROP) and pramipexole (PPX) extended release) in an European real life population base (target=500).

BACKGROUND:
• Tolerability/retention rate of recently introduced longer acting DA are unknown in real life clinical populations which include patients over 75 years of age.
• Tolerability can be addressed by criteria as used by Shulman et al.¹ (treatment classed as “tolerated” if sustained for six months or more)
• Specifically side effect issues such as development of impulse control disorder (ICD) during treatment with longer acting DA and tolerability of non oral DA such as RTG in patients with swallowing difficulties have not been studied.

RESULTS 1:
• 69 of 107 assessable patients (83.2%) on RTG tolerated the drug, 82/89 (92.1%) tolerated ROP XL and 25/28 tolerated PPX PR (89.3%).
• 26 of the 282 evaluated cases (9.3%) report successful tolerability of 2 DA (oral plus patch).

RESULTS 2:
• 22 cases (7.8%) reported impulse control disorders (ICD), most were exposed to oral DA.
• Discontinuation due to ICD was reported in 2/126 cases (1.6%) on RTG, 3/109 cases (2.8%) on ROP XL and 1/34 cases (2.9%) on PPX PR.
• 4 cases with ICD on PPX /ROP reported attenuation of ICD when started on RTG patch.
• 19 of 69 assessed patients suffered from swallowing difficulties, 17 of which preferred patch to oral therapy. 69% of those tolerated RTG.

CONCLUSIONS: This ongoing survey reveals a good tolerability rate of all longer acting DAs particularly in older (≥75yrs) PD including dual agonist use. RTG use is particularly tolerated in those with swallowing difficulties. ICD rates are low and in some, reversal is reported after switching to RTG.